Novel Lipoprotein (a) Therapies: A Comprehensive Review.
Level 5 - mechanism / opinion, no new human data
Narrative review of clinical trial pipelines without systematic review or meta-analysis methodology.
PubMed 42593611 · doi:10.1007/s11883-026-01453-9
What was done
This narrative review synthesized phase 1 to 3 trial data, trial registries, and regulatory updates through mid-2026 covering targeted lipoprotein(a) [Lp(a)]-lowering therapies, including antisense oligonucleotides, small interfering RNAs (siRNAs), an oral small molecule, and CRISPR/Cas9 gene-editing approaches.
What was found
Five therapeutic agents across three mechanisms are in late-stage development: - Pelacarsen (GalNAc-conjugated antisense oligonucleotide) reduces Lp(a) by approximately 80%, with phase 3 HORIZON outcomes trial results anticipated in late 2026. - Three siRNAs demonstrated profound reductions: olpasiran (>95%), lepodisiran (93.9% sustained for over 12 months after a single dose), and zerlasiran (96.4%). - Muvalaplin (oral small-molecule inhibitor of apo(a)-ApoB assembly) reduced intact Lp(a) by up to 85.8% in phase 2 trials, with a phase 3 trial initiated. - CTX320 (CRISPR/Cas9 gene editing) entered phase 1 testing. All agents exhibited acceptable preliminary safety profiles.
Why it matters
Lp(a) is a highly heritable, independent driver of atherosclerotic disease and calcific aortic valve stenosis that is largely unresponsive to statins and lifestyle interventions. These potent agents provide a means to test whether lowering Lp(a) translates into hard clinical cardiovascular event reductions.
Limits
The review lacks systematic literature search and meta-analytic methods. Total participant counts, detailed adverse event frequencies, and confidence intervals are not reported in the abstract. Clinical efficacy on major adverse cardiovascular events remains unconfirmed until ongoing phase 3 cardiovascular outcomes trials conclude.
Cited by
- supports Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein.